{"title":"The TRUFFLE monitoring protocol for early-onset fetal growth restriction: A clinical effectiveness study.","authors":"Claire Pegorie, Basia Chmielewska, Michelle Jie, Nishita Mehta, Daniel McStay, Amar Bhide, Basky Thilaganathan","doi":"10.1111/aogs.70240","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The randomized control Trial (RCT) of Randomized Umbilical and Fetal Flow in Europe (TRUFFLE study) established its clinical efficacy for monitoring preterm fetal growth restriction (FGR). The objective of this study was to assess the clinical effectiveness of this protocol in a routine clinical setting with regards to the clinical outcomes, both overall and stratified by gestational age at FGR diagnosis.</p><p><strong>Material and methods: </strong>This is a retrospective cohort study of singleton pregnancies with preterm FGR between January 2013 and July 2024 in a tertiary Fetal Medicine Unit. FGR was defined as an estimated fetal weight or abdominal circumference <10th centile with an elevated umbilical artery pulsatility index >95th centile. Main outcomes collected included perinatal survival, interval from diagnosis to delivery, and delivery indications.</p><p><strong>Results: </strong>171 pregnancies met inclusion criteria. The median (IQR) gestation at FGR diagnosis and birth was 27<sup>+6</sup> (25<sup>+5</sup>-29<sup>+4</sup>) and 30<sup>+3</sup> (28<sup>+0</sup>-32<sup>+4</sup>) weeks, respectively. Overall intact neonatal survival was 90.6%, with the rate of stillbirth and neonatal death being 2.9% and 5.8%, respectively. FGR diagnosis prior to 26 weeks was associated with a three-fold longer interval to birth compared with FGR diagnosis at 26<sup>+0</sup>-29<sup>+6</sup> and ≥30 weeks (median of 31.0 vs. 10.0 and 14.0 days; p < 0.001). Below 32 weeks, the predominant indication for elective birth was abnormal computerized CTG with low short-term variation (STV). Beyond 32 weeks' gestation, abnormal umbilical artery Doppler and maternal indications such as preeclampsia were more frequent.</p><p><strong>Conclusions: </strong>The TRUFFLE monitoring protocol is clinically effective in managing early-onset FGR outside a trial environment, achieving comparable perinatal outcomes to the original RCT. Routine integration of both Doppler and cCTG monitoring is crucial for optimal timing of birth with early FGR. Further research is needed to explore the benefits of more frequent or remote fetal monitoring.</p>","PeriodicalId":6990,"journal":{"name":"Acta Obstetricia et Gynecologica Scandinavica","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Obstetricia et Gynecologica Scandinavica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/aogs.70240","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The randomized control Trial (RCT) of Randomized Umbilical and Fetal Flow in Europe (TRUFFLE study) established its clinical efficacy for monitoring preterm fetal growth restriction (FGR). The objective of this study was to assess the clinical effectiveness of this protocol in a routine clinical setting with regards to the clinical outcomes, both overall and stratified by gestational age at FGR diagnosis.
Material and methods: This is a retrospective cohort study of singleton pregnancies with preterm FGR between January 2013 and July 2024 in a tertiary Fetal Medicine Unit. FGR was defined as an estimated fetal weight or abdominal circumference <10th centile with an elevated umbilical artery pulsatility index >95th centile. Main outcomes collected included perinatal survival, interval from diagnosis to delivery, and delivery indications.
Results: 171 pregnancies met inclusion criteria. The median (IQR) gestation at FGR diagnosis and birth was 27+6 (25+5-29+4) and 30+3 (28+0-32+4) weeks, respectively. Overall intact neonatal survival was 90.6%, with the rate of stillbirth and neonatal death being 2.9% and 5.8%, respectively. FGR diagnosis prior to 26 weeks was associated with a three-fold longer interval to birth compared with FGR diagnosis at 26+0-29+6 and ≥30 weeks (median of 31.0 vs. 10.0 and 14.0 days; p < 0.001). Below 32 weeks, the predominant indication for elective birth was abnormal computerized CTG with low short-term variation (STV). Beyond 32 weeks' gestation, abnormal umbilical artery Doppler and maternal indications such as preeclampsia were more frequent.
Conclusions: The TRUFFLE monitoring protocol is clinically effective in managing early-onset FGR outside a trial environment, achieving comparable perinatal outcomes to the original RCT. Routine integration of both Doppler and cCTG monitoring is crucial for optimal timing of birth with early FGR. Further research is needed to explore the benefits of more frequent or remote fetal monitoring.
简介:欧洲随机脐带和胎儿流量随机对照试验(TRUFFLE study)确定了其监测早产胎儿生长受限(FGR)的临床疗效。本研究的目的是评估该方案在常规临床环境中的临床效果,包括FGR诊断时的总体和按胎龄分层的临床结果。材料和方法:这是一项2013年1月至2024年7月在第三胎医学单位进行的单胎妊娠早产FGR的回顾性队列研究。FGR的定义为胎儿体重或腹围第95百分位。收集的主要结局包括围产儿生存、诊断至分娩的时间间隔和分娩指征。结果:171例妊娠符合纳入标准。FGR诊断和分娩时的中位妊娠(IQR)分别为27+6(25+5-29+4)和30+3(28+0-32+4)周。新生儿整体完整存活率为90.6%,死产和新生儿死亡率分别为2.9%和5.8%。与26+0-29+6和≥30周的FGR诊断相比,26周前的FGR诊断与出生间隔延长3倍相关(中位数为31.0 vs. 10.0和14.0天;p)结论:TRUFFLE监测方案在临床有效地管理试验环境外的早发性FGR,获得与原始RCT相当的围产期结果。多普勒和cCTG监测的常规整合对于早期FGR的最佳出生时间至关重要。需要进一步的研究来探索更频繁或远程胎儿监测的好处。
期刊介绍:
Published monthly, Acta Obstetricia et Gynecologica Scandinavica is an international journal dedicated to providing the very latest information on the results of both clinical, basic and translational research work related to all aspects of women’s health from around the globe. The journal regularly publishes commentaries, reviews, and original articles on a wide variety of topics including: gynecology, pregnancy, birth, female urology, gynecologic oncology, fertility and reproductive biology.